Edition:
United States

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,690JPY
10:29pm EDT
Change (% chg)

¥-50 (-0.87%)
Prev Close
¥5,740
Open
¥5,790
Day's High
¥5,790
Day's Low
¥5,680
Volume
268,000
Avg. Vol
868,558
52-wk High
¥6,080
52-wk Low
¥3,895

Chart for

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as... (more)

Overall

Beta: 0.67
Market Cap(Mil.): ¥3,190,210.00
Shares Outstanding(Mil.): 559.69
Dividend: 31.00
Yield (%): 1.09

Financials

  4519.T Industry Sector
P/E (TTM): 42.91 29.65 32.31
EPS (TTM): 132.83 -- --
ROI: 10.43 13.36 12.97
ROE: 10.87 15.09 14.84

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei‍​

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI‍​ Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)

Dec 28 2017

BRIEF-Chiome Bioscience says termination of joint research contract

* Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD, as the contract has expired on Dec. 31

Dec 18 2017

BRIEF-Chugai Pharmaceutical says change of chief executive officer

* Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018

Dec 12 2017

BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I

Nov 16 2017

Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo

ZURICH, Nov 14 Chugai Pharmaceuticals, a Japan-based Roche subsidiary, said on Tuesday it has agreed to transfer the marketing and manufacturing right of 13 long-term listed products to Taiyo Holdings' Taiyo Pharma.

Nov 14 2017

BRIEF-Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma

* Says it and TAIYO HOLDINGS CO LTD announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings

Nov 14 2017

BRIEF-Chugai Pharma considering selling production rights of some medications to Taiyo - Nikkei

* Chugai Pharma considering selling production, sales rights of some 15 medications with expired patents to Taiyo Holdings for about 20 billion yen - Nikkei Source text : (http://s.nikkei.com/2iRwewI) Further company coverage:

Nov 13 2017

Earnings vs. Estimates